ArtNr |
PTM-6786 |
Hersteller |
PTM Biolabs
|
Menge |
100 ul |
Format |
Lyophilized powder |
Applikationen |
WB |
Specific against |
Human (Homo sapiens), Rat (Rattus norvegicus) |
Host |
Rabbit |
Isotype |
IgG |
Konjugat/Tag |
Unconjugated |
Alias |
Hsp90 co-chaperone Cdc37, p50Cdc37, CDC37A |
Versandbedingung |
Raumtemperatur |
Lieferbar |
|
Manufacturer - Type |
Primary Antibodies |
Manufacturer - Category |
Uncategorized |
Manufacturer - Targets |
Cdc37 |
Shipping Temperature |
Ambient temperature |
Storage Conditions |
Store at -20°C. Avoid freeze/thaw cycles. |
Manufacturer - Research Area |
Cell Biology, Epigenetics |
Product description |
CDC37 is an important component of the HSP90 chaperone complex. It was initially identified for its involvement in cell-cycle progression and was later found to have a much broader role as a chaperone for a wide variety of kinases and other proteins. CDC37 protein has an amino-terminal kinase binding domain followed by a central HSP90 binding domain. It recruits and stabilizes kinases in the HSP90 complex by protecting the newly synthesized kinase peptide chain from degradation and promoting the next step of protein maturation. CDC37 also suppresses the ATPase activity of HSP90, thereby leading to conformational changes in the complex that preclude target kinase loading. CDC37 has been proposed as a therapeutic target because of its important role in multiple kinase pathways involved in proliferation and cancer cell survival, including Raf, Akt, Src, and ErbB2 pathways. Moreover, CDC37 is phosphorylated by CKII at its carboxy-terminal Ser13 residue, which is required for its interaction with HSP90 and target protein stabilization function. |
Purification Method |
Protein A purified |
Constituents |
PBS, Glycerol, BSA |
PTM |
Phospho |
Modification Site |
Ser13 |
Clonality |
Polyclonal |
Stability |
Stable for 12 months from date of receipt/reconstitution. |
Background |
CDC37 is an important component of the HSP90 chaperone complex. It was initially identified for its involvement in cell-cycle progression and was later found to have a much broader role as a chaperone for a wide variety of kinases and other proteins. CDC37 protein has an amino-terminal kinase binding domain followed by a central HSP90 binding domain. It recruits and stabilizes kinases in the HSP90 complex by protecting the newly synthesized kinase peptide chain from degradation and promoting the next step of protein maturation. CDC37 also suppresses the ATPase activity of HSP90, thereby leading to conformational changes in the complex that preclude target kinase loading. CDC37 has been proposed as a therapeutic target because of its important role in multiple kinase pathways involved in proliferation and cancer cell survival, including Raf, Akt, Src, and ErbB2 pathways. Moreover, CDC37 is phosphorylated by CKII at its carboxy-terminal Ser13 residue, which is required for its interaction with HSP90 and target protein stabilization function. |
Cellular Localization |
Cytoplasm, Nucleus |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.